Persistent Health Differences Seen Between Females and Males
By Elana Gotkine HealthDay Reporter
FRIDAY, May 3, 2024 -- From 1990 to 2021, there were persistent health differences between females and males, according to a study published online May 1 in The Lancet Public Health.
Vedavati Patwardhan, Ph.D., from the University of California, San Diego, and colleagues compared disability-adjusted life year (DALY) rates among females and males aged older than 10 years for the 20 leading causes of disease burden at the global level and across seven world regions between 1990 and 2021 using the Global Burden of Disease Study 2021.
The researchers found that females had a higher burden of morbidity-driven conditions globally, with the largest differences in DALYs for low back pain, depressive disorders, and headache disorders (478.5, 348.3, and 332.9 more DALYs per 100,000 individuals among females than males), while males had higher DALY rates for mortality-driven conditions, with the largest differences for COVID-19, road injuries, and ischemic heart disease (1,767.8, 1,012.2, and 1,611.8 more DALYs per 100,000 among males than females). With age, the differences became larger; for all conditions apart from HIV/AIDS, they remained consistent over time.
"As the global population ages, progress towards an equitable and healthy future for all can only be achieved through concerted, sex-informed and gender-informed strategies that recognize the distinct health challenges faced by men and women at different stages of life," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
342 Cardiology Clinics Acquired by Private Equity Firms in 2013 to 2023
WEDNESDAY, July 3, 2024 -- From 2013 to 2023, 342 cardiology clinics were acquired by private equity firms, with 94.7 percent of the acquisitions occurring between 2021 and 2023...
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.